Research programme: subtype-selective NMDA receptor antagonists - Purdue Pharma/Senju

Drug Profile

Research programme: subtype-selective NMDA receptor antagonists - Purdue Pharma/Senju

Latest Information Update: 03 Sep 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer; Purdue Pharma
  • Developer Purdue Pharma; Senju Pharmaceutical
  • Class
  • Mechanism of Action Glutamate receptor antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cerebral ischaemia; Epilepsy; Eye-Disorders; Neurological disorders; Pain; Parkinson's disease

Most Recent Events

  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
  • 16 Nov 1999 CoCensys has been acquired by Purdue Pharma
  • 27 May 1999 A lead compound from this programme has been identified
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top